Abstract:Canine parvovirus (CPV) is a single-stranded DNA virus that can cause typical hemorrhagic enteritis, and it is one of the common canine lethal viruses. In previous studies, we screened the Food and Drug Administration (FDA)'s drug library and identified nitazoxanide (NTZ), which has anti-CPV capabilities. To investigate the potential antiviral mechanisms, we first reconfirmed the inhibitory effect of NTZ on the CPV by inoculating with different doses and treating for different lengths of time. Then, the differences in the transcription levels between the 0.1%-DMSO-treated virus group and the NTZ-treated virus group were detected using RNA-seq, and a total of 758 differential expression genes (DEGs) were finally identified. Further Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the DEGs revealed that these genes are involved in a variety of biological processes and/or signaling pathways, such as cell cycle, mitosis and cell proliferation and differentiation. A protein–protein interaction (PPI) analysis further identified hub genes associated with cell cycle and division among the DEGs. In addition, the expression levels of some of the enriched genes were detected, which were consistent with the high-throughput sequencing results. Moreover, when the cell cycle was regulated with cell cycle checkpoint kinase 1 (Chk1) inhibitor MK-8776 or Prexasertib HCl, both inhibitors inhibited the CPV. In summary, the transcriptome differential analysis results presented in this paper lay the foundation for further research on the molecular mechanism and potential targets of NTZ anti-CPV.

Soluble Form of Canine Transferrin Receptor Inhibits Canine Parvovirus InfectionIn VitroandIn Vivo

Inhibition of canine parvovirus 2 (CPV-2) replication by TAT-scFv through targeting of the viral structural protein VP2 of CPV-2

Study On The Tissue Tropism Of Canine Parvovirus Based On The Distribution Of The Transferrin Receptors

Inhibition of canine parvovirus replication in cultured cells by small interfering RNAs expressed from plasmid vectors.

Vaccination therapy of Canine Parvovirus (CPV) infected on dogs

Canine Parvovirus is diagnosed and neutralized by chicken IgY-scFv generated against the virus capsid protein

Magnetic Resonance Imaging Revealed Splenic Targeting of Canine Parvovirus Capsid Protein VP2

Isolation and identification of canine parvovirus strain HZ0761

Molecular Biology of Canine Parainfluenza Virus V Protein and Its Potential Applications in Tumor Immunotherapy

Expression, Purification, and Characterization of VP2 Capsid Protein of Canine Parvovirus in Escherichia Coli

Enhancing the antivirus activity of chimeric canine interferon with ricin subunit B by using nanoparticle formulations.

Identification of Two Isoforms of Canine Tetherin in Domestic Dogs and Characterization of Their Antiviral Activity against Canine Influenza Virus

Canine Circovirus Suppresses the Type I Interferon Response and Protein Expression but Promotes CPV-2 Replication

Chaperonin TRiC/CCT subunit CCT7 is involved in the replication of canine parvovirus in F81 cells

Trigger factor assisted self-assembly of canine parvovirus VP2 protein into virus-like particles in Escherichia coli with high immunogenicity

A canine-derived chimeric antibody with high neutralizing activity against canine parvovirus-2

Canine immunoglobulin F(ab′)2 fragments protect cats against feline parvovirus virus infection

Transcriptional Differential Analysis of Nitazoxanide-Mediated Anticanine Parvovirus Effect in F81 Cells

Identification of Feline Interferon Regulatory Factor 1 as an Efficient Antiviral Factor against the Replication of Feline Calicivirus and Other Feline Viruses

Development of an Indirect Enzyme-Linked Immunosorbent Assay (ELISA) Assay Based on a Recombinant Truncated VP2 (tvp2) Protein for the Detection of Canine Parvovirus Antibodies

Tumor targeting using canine parvovirus nanoparticles